Summary: In this exploratory secondary analysis of two Phase 2 randomised trials, the oral GLP-1 receptor agonist orforglipron was associated with significant placebo-adjusted reductions in blood pressure, LDL cholesterol, triglycerides, apolipoprotein B, apolipoprotein C3, and high-sensitivity C-reactive protein in adults with type 2 diabetes (N=361) or with overweight/obesity without diabetes (N=234). These are surrogate cardiovascular risk biomarkers, not cardiovascular events, so the data are hypothesis-generating rather than confirmatory.
PICO Summary
| Element | Detail |
|---|---|
| Population | Pooled exploratory biomarker analysis of participants with available samples from two Phase 2 randomised trials: type 2 diabetes (N=361; mean age 59 years, 40% female, mean HbA1c 8.1%, mean BMI 35.3 kg/m2) and overweight/obesity without diabetes (N=234; mean age 54 years, 60% female, mean BMI 37.9 kg/m2). Trials NCT05048719 and NCT05051579. |
| Intervention | Once-daily oral orforglipron at 3, 12, 24, 36, or 45 mg (12-45 mg in the obesity trial), assessed at 26 weeks (diabetes) or 36 weeks (obesity). |
| Comparison | Placebo; the diabetes trial additionally included once-weekly subcutaneous dulaglutide 1.5 mg as an active reference arm. |
| Outcome | Significant placebo-adjusted decreases from baseline were reported for blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP in participants with type 2 diabetes and with overweight/obesity. Improvements with 12 mg were of similar magnitude to those with 24, 36, and 45 mg. The abstract reports directional significance qualitatively and does not provide point estimates, 95% confidence intervals, p-values, or ARR/NNT; no cardiovascular events were assessed, so no absolute risk reduction is calculable. |
Expert Commentary
This is an exploratory, secondary biomarker analysis drawn from two Phase 2 trials, and it should be read as hypothesis-generating rather than as evidence of cardiovascular benefit. The verdict is that orforglipron consistently moved several recognised cardiovascular risk markers in a favourable direction, with reductions in blood pressure, atherogenic lipids, apolipoproteins, and an inflammatory marker that are biologically coherent for an effective incretin agonist. The most important limitation is that surrogate biomarkers are not clinical outcomes; lower LDL, triglycerides, and hsCRP predict, but do not establish, fewer heart attacks, strokes, or deaths, and only a dedicated cardiovascular outcomes trial can confirm that link. The analysis was funded by the manufacturer and most authors are company employees, the trials were short and Phase 2 in scale, and the lack of reported effect sizes and confidence intervals in the abstract limits independent appraisal. Can I use this with my patients? Not yet as a reason to prescribe for heart protection; for a patient with type 2 diabetes or obesity who is already a candidate for a GLP-1 agonist, these data are reassuring about metabolic direction but should not be presented as proven cardiovascular benefit. Clinicians should await the Phase 3 programme and cardiovascular outcomes data before drawing firm conclusions.
References
Wharton S, Rosenstock J, Konige M, Lin Y, Duffin K, Wilson J, et al. Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025;24(1):240. doi:10.1186/s12933-025-02781-x
